Mycamine (micafungin) is a systemic antimycotic indicated for invasive candidiasis, oesophageal candidiasis and prophylaxis of candida infection.

Mycamine inhibits the synthesis of 1,3-B-D-glucan, an essential component of the fungal cell wall.

Treatment must be initiated by a specialist and the decision to use Mycamine should take into account a potential risk of developing liver tumours. Liver function must be carefully monitored throughout treatment.

Treatment indications:

  • Invasive candidiasis in adults and children.
  • Oesophageal candidiasis in patients aged >16 years where iv therapy is appropriate.
  • Prophylaxis of candida infection in adults and children undergoing allogeneic haematopoietic stem cell transplantation or patients expected to have neutropenia for >10 days.

View Mycamine drug record

Further information: Astellas

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases